Roche Holding AG (SWX: RO)
302.20
-0.60 (-0.20%)
Sep 4, 2024, 5:30 PM CET
Roche Holding AG Company Description
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.
The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.
It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions.
Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
Roche Holding AG
![Roche Holding AG logo](https://img.stockanalysis.com/logos1/SW/RO.png)
Country | Switzerland |
Founded | 1896 |
Industry | Drug Manufacturers - General |
Sector | Healthcare |
Employees | 103,605 |
CEO | Thomas Schinecker |
Contact Details
Address: Grenzacherstrasse 124 Basel, 4058 Switzerland | |
Phone | 41 61 688 11 11 |
Website | roche.com |
Stock Details
Ticker Symbol | RO |
Exchange | SIX Swiss Exchange |
Fiscal Year | January - December |
Reporting Currency | CHF |
ISIN Number | CH0012032113 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Thomas Schinecker | Chief Executive Officer |
Dr. Severin Schwan Ph.D. | Executive Chairman |
Dr. Alan Hippe | Chief Financial and Information Officer |
Dr. Bruno Eschli | Head of Investor Relations |
Claudia Bockstiegel | General Counsel |
Pascale Schmidt | Chief Compliance Officer |
Barbara Schadler | Head of Group Communications |
Cristina A. Wilbur | Chief People Officer |
Dr. Nicolas Dunant | Head of Group Media Relations |
Boris L. Zaitra | Head of Corporate Business Development |